Business
OS Therapies Announces Positive Biomarker Data from Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
Activation of immune blood biomarkers from interferon gamma pathway distinguished long term survivors (>=2 years) from short-term survivors (<1year)Pre-specified pathway analysis strategy developed as a result of immune biomarker pathway data generated from 118-patient canine metastatic osteosarcoma study published in February 2025 demonstrates translational power of Comparative Oncology to identify surrogate markers of clinical efficacyNew York, New York--(Newsfile Corp. - January 15, 2026) -..
About this update from Os Therapies Incorporated
[{"type":"list","items":[{"val":[{"type":"text","content":"Activation of immune blood biomarkers from interferon gamma pathway distinguished long term survivors (>=2 years) from short-term survivors (<1year)","length":154,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Pre-specified pathway analysis strategy developed as a result of immune biomarker pathway data generated from 118-patient canine metastatic osteosarcoma study published in February 2025 demonstrates translational power of Comparative Oncology to identify surrogate markers of clinical efficacy","length":293,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":447,"olType":false},{"type":"text","content":"New York, New York--(Newsfile Corp. - January 15, 2026) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), the world leader in listeria-based cancer immunotherapies, today announced positive biomarker data from its Phase 2b clinical trial of OST-HER2 in the prevention or delay of recurrent, fully resected, pulmonary metastatic osteosarcoma (the "Human Metastatic Osteosarcoma Trial"). Activation of immune blood biomarkers in the interferon gamma pathway was predictive of overall survival, distinguishing long term survivors (>=2 years) from short-term survivors (<1year). The Company's pre-specified pathway analysis strategy that was developed as a result of immune biomarker pathway data generated from 118-patient canine metastatic osteosarcoma study published in February 2025 (the "Canine Metastatic Osteosarcoma Trial") demonstrates the translational power of Comparative Oncology in identifying surrogate markers of clinical efficacy for human osteosarcoma clinical development programs.","length":1074,"tagName":"p"},{"type":"text","content":""Leveraging the power of Comparative Oncology, we were able to train and test potentially predictive biomarkers from the Canine Metastatic Osteosarcoma Trial in order to form a hypothesis to test in a pre-specified way in the Human Metastatic Osteosarcoma Trial," said Paul Romness, MHP, Chairman & CEO of OS Therapies. "We believe the confirmation of this pre-specified pathway analysis in humans adds significant resolution to our clinical data, increasing the clinical interpretability of the 2-year overall survival data f...